Vanguard Personalized Indexing Management
RXRX icon

Vanguard Personalized Indexing Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108K Sell
29,518
-4,346
-13% -$14.5K ﹤0.01% 2042
2026
Q1 		$104K Buy
33,864
+23,286
+220% +$90K ﹤0.01% 1945
2025
Q4 		$43.3K Sell
10,578
-678
-6% -$3.36K ﹤0.01% 1897
2025
Q3 		$54.9K Sell
11,256
-897
-7% -$4.71K ﹤0.01% 1893
2025
Q2 		$61.5K Sell
12,153
-2,570
-17% -$12.6K ﹤0.01% 1801
2025
Q1 		$77.9K Buy
14,723
+3,284
+29% +$23.9K ﹤0.01% 1645
2024
Q4 		$77.3K Buy
+11,439
New +$76.9K ﹤0.01% 1645

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Personalized Indexing Management's RXRX Position: Q2 2026 in Review

Vanguard Personalized Indexing Management reduced its Recursion Pharmaceuticals (RXRX) stake by 13% in Q2 2026, selling an estimated $14.5K and leaving 29,518 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #2042.

Vanguard Personalized Indexing Management first reported a position in RXRX in Q4 2024 and has held it in 7 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Vanguard Personalized Indexing Management held 29,518 shares of Recursion Pharmaceuticals worth $108K as of Q2 2026.
  • Vanguard Personalized Indexing Management sold 4,346 Recursion Pharmaceuticals shares in Q2 2026, an estimated $14.5K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #2042 holding.
  • Vanguard Personalized Indexing Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.